You are here

Notice of final decisions to amend (or not amend) the current Poisons Standard - ACMS #34, Joint ACMS-ACCS #28, ACCS #31

20 December 2021

This web publication constitutes a notice for the purposes of regulation 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS, this notice publishes the:

  • decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR;
  • reasons for those final decisions; and
  • date of effect of those decisions.

Final decision in relation to sodium nitrite

Note that the final decision for sodium nitrite is not published in this notice. The final decision for sodium nitrite has been delayed and is anticipated for publication in late January.

Final decisions and reasons

We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.

Contents

  • 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
  • 2 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #34, June 2021)
    • 2.1 Final decision in relation to amygdalin and hydrocyanic acid
    • 2.2 Final decision in relation to bufexamac
    • 2.3 Final decision in relation to ibuprofen
    • 2.4 Final decision in relation to oral contraceptive substances
  • 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #28, June 2021)
    • 3.1 Final decision in relation to ethanol and isopropanol in hand sanitisers
    • 3.2 Final decision in relation to methanol in hand sanitisers
    • 3.3 Final decision in relation to eugenol
  • 4 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #31, June 2021)
    • 4.1 Final decision in relation to 2-amino-5-methylphenol
    • 4.2 Final decision in relation to 6-methoxy-N2-methyl-2,3-pyridinediamine
    • 4.3 Final decision in relation to lead acetates